Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections

Middle East respiratory syndrome coronavirus (MERS-CoV) infections in humans can cause asymptomatic to fatal lower respiratory lung disease. Despite posing a probable risk for virus transmission, asymptomatic to mild infections can go unnoticed; a lack of seroconversion among some PCR-confirmed cases has been reported. We found that a MERS-CoV spike S1 protein–based ELISA, routinely used in surveillance studies, showed low sensitivity in detecting infections among PCR-confirmed patients with mild clinical symptoms and cross-reactivity of human coronavirus OC43–positive serum samples. Using in-house S1 ELISA and protein microarray, we demonstrate that most PCR-confirmed MERS-CoV case-patients with mild infections seroconverted; nonetheless, some of these samples did not have detectable levels of virus-neutralizing antibodies. The use of a sensitive and specific serologic S1-based assay can be instrumental in the accurate estimation of MERS-CoV prevalence.

Abstract licence: CC BY

• Immunity to SARS‐CoV‐2 induced by infection or vaccination · 2021

• The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection · 2020

• A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity · 2020

• Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020

• Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients · 2020

• Corrected

  A human monoclonal antibody blocking SARS-CoV-2 infection · 2020

• Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome · 2020

• From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach · 2020

• Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development · 2020

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.